Use of a linearization approximation facilitating stochastic model building.
E.M. Svensson , M.O. Karlsson. Journal of Pharmacokinetcs and Pharmacodynamics 2014, 41: 153
The objective of this work was to facilitate the development of nonlinear mixed effects models by establishing a... Read more
Biophysical constraints on the evolution of tissue structure and function. P. J. Hunter and B. de Bono Abstract
Phylogenetic analyses based on models of molecular sequence evolution have driven to industrial scale the generation, cataloguing and modelling of nucleic acid and polypeptide structure.... Read more
Modeling of 24-Hour Glucose and Insulin Profiles in Patients With Type 2 Diabetes Mellitus Treated With Biphasic Insulin Aspart.
Rikke M. Røge, Søren Klim, Niels R. Kristensen, Steen H. Ingwersen, and Maria C. Kjellsson.
Insulin therapy for diabetes patients is designed to mimic the... Read more
A note on BIC in mixed-effects models
Maud Delattre, Marc Lavielle and Marie-Anne Poursat
The Bayesian Information Criterion (BIC) is widely used for variable selection in mixed effects models. However, its expression is unclear in typical situations of mixed effects models, where simple... Read more
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis.
B Ribba, NH Holford, P Magni, I Trocóniz, I Gueorguieva, P Girard, C Sarr, M Elishmereni, C Kloft and LE Friberg CPT:Pharmacometrics and Systems Pharmacology, 2014, e113Abstract... Read more
A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients
Núria Buil-Bruna, José-María López-Picazo, Marta Moreno-Jiménez, Salvador Martín-Algarra, Benjamin Ribba, and Iñaki F. Trocóniz AAPSJ
The... Read more
Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments
JB Møller, RV Overgaard, MC Kjellsson, NR Kristensen, S Klim, SH Ingwersen and MO Karlsson
Late-phase clinical trials within diabetes generally have a duration of 12–24 weeks,... Read more
Posted on 19 December 2013 | Filed under: WP3, WP4
Leiden, the Netherlands, 20th December 2013 – The IMI Drug Disease Model Resources (DDMoRe) consortium is launching modelling languages to enable quantitative decision making across all stages of pharmaceutical drug development. This first release includes a “universal” Modelling Description... Read more
Population pharmacokinetic pharmacodynamic modelling in oncology: a tool for predicting clinical response1
B C Bender, E Schindler, L E Friberg. Br. J. Clin. Pharmacol.
In oncology trials, overall survival (OS) is considered the most reliable and preferred endpoint to evaluate the benefit... Read more
Support was received from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115156, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners